Shows inhibition of ferroptosis in neutrophilic asthma, suggesting improved treatment options.
Ferroptosis is an iron-dependent programmed cell death mechanism triggered by the accumulation of lipid-based reactive oxygen species (ROS). It is closely implicated in the pathogenesis of asthma. Liproxstatin-1 (LIP-1) is a ferroptosis inhibitor that is beneficial for treating neutrophilic asthma. However, low water solubility, limited blood concentration, and poor mucus permeability and biocompatibility limit the therapeutic efficacy of LIP-1. In this study, we successfully constructed polydopamine–polyethylene glycol–LIP-1 nanoparticles (PDA-PEG-LIP-1 NPs) for the treatment of neutrophilic asthma. Inhalation of PDA-PEG-LIP-1 NPs effectively inhibited lipopolysaccharide (LPS)- and interleukin (IL)-13-induced ferroptosis by alleviating lipid peroxidation and ROS production and chelating free ferrous ions (Fe 2+ ). In addition, results from asthma mouse models demonstrated that inhalation of PDA-PEG-LIP-1 NPs could overcome the limitations of LIP-1 and effectively inhibit ferroptosis. This research suggests that PDA-PEG-LIP-1 NPs are an effective, practical, and safe option for treating neutrophilic asthma.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: